MEDIQ

Acquisitions must match our strategy. We first analyse the attractiveness of the market, for which purposes national statutory and regulatory provisions governing for instance the reimbursement system in healthcare are often the leading criteria. We consider how competent the target company’s management is and whether it fits in with the corporate culture of our group. In addition, we apply stringent financial criteria, including the general requirement that the acquisition should generate a return of at least 15% before tax on average capital employed within a limited number of years. We aim to reach that level of returns after two years at the latest from additions to existing platforms.

We are actively seeking acquisition opportunities in the Direct & Institutional segment, preferably in countries where we already have a presence. We see the greatest opportunities for doing so in Germany, Scandinavia and the USA.
We approach acquisition opportunities selectively in the pharmacy markets in the Netherlands and Poland. The assessment of acquisition opportunities is based on our location strategy.